ReNeuron jumps on stem cell trial start

ReNeuron Group plc (LSE:RENE) jumped 2.95p (60%) to 7.85p on Tuesday after starting the Phase I PISCES trial of ReN001 stem cell therapy to treat patients disabled by ischemic stroke. The U.K. trial w...